Skandinaviska Enskilda Banken AB publ Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

Skandinaviska Enskilda Banken AB publ decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 131,592 shares of the medical research company's stock after selling 19,336 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.07% of IQVIA worth $25,983,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in IQV. Raymond James Financial Inc. purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $236,120,000. FMR LLC boosted its position in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter worth approximately $147,683,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 1.9 %

Shares of NYSE IQV traded up $3.55 during mid-day trading on Tuesday, reaching $188.45. The company had a trading volume of 1,344,794 shares, compared to its average volume of 1,448,378. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50 day simple moving average of $196.34 and a two-hundred day simple moving average of $209.96. The stock has a market cap of $33.23 billion, a P/E ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.34.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IQV shares. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Leerink Partners reiterated an "outperform" rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.